Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Apatinib, and Eribulin in Advanced Triple-Negative Breast Cancer
NCT06889688Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, Rivoceranib, eribulin in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen Memorial Hospital. Started Feb 2025; status: recruiting.
02
Drugs
camrelizumabRivoceraniberibulin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06889688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06889688.